# Chemours Co: Form 10-Q for the period ended Sep 30, 2019

- Company: [Chemours Co](/companies/cc.md) (CIK 1627223)
- Form: 10-Q
- Filed: 2019-11-05
- Accepted by EDGAR: Nov 5, 2019, 17:11 ET
- Period: 2019-09-30
- Accession: 0001564590-19-040478
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1627223/000156459019040478/cc-10q_20190930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1627223/000156459019040478/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $1.39bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $4.17bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $1.10bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $3.26bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $294.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $913.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $20.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $61.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-30 | $130.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-30 | $423.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $53.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $156.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $15.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $65.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $76.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | $265.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.46 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | $1.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.46 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | $1.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 165,140,863 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 168,034,958 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $250.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $385.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2019-01-01 to 2019-09-30 | $322.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-09-30 | $694.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $2.83bn | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $7.46bn | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $1.64bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $6.61bn | us-gaap:Liabilities |
| Long-term debt | at 2019-09-30 | $4.01bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2019-09-30 | $149.0m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2019-09-30 | $837.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 80,679 characters.

*This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) supplements the unaudited Interim Consolidated Financial Statements and the related notes thereto included elsewhere herein to help provide an understanding of our financial condition, changes in our financial condition, and the results of our operations for the periods presented. Unless the context otherwise requires, references herein to “The Chemours Company,” “Chemours,” “the Company,” “our Company,” “we,” “us,” and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refer to E. I. du Pont de Nemours and Company, a Delaware corporation.*

*This MD&A should be read in conjunction with the unaudited Interim Consolidated Financial Statements and the related notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as our audited Consolidated Financial Statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.*

*This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe,” “expect,” “anticipate,” “plan,” “estimate,” “target,” “project,” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements.*

*Our forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond our control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include, but are not limited to, the risks, uncertainties, and other factors discussed in the Forward-looking Statements and the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, 2018, and otherwise as discussed in this report and our Annual Report on Form 10-K. We assume no obligation to revise or update any forward-looking statement for any reason, except as required by law.*

### Overview

We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. Our principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates, and titanium dioxide (“TiO2”) pigment. We manage and report our operating results through three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. Our Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. Our Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications. Our Titanium Technologies segment is a leading, global provider of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.

We are committed to creating value for our customers and stakeholders through the reliable delivery of high-quality products and services around the world. To achieve this goal, we have a global team dedicated to upholding our five core values: (i) ***customer centricity –*** driving customer growth, and our own, by understanding our customers’ needs and building long-lasting relationships with them; (ii) ***refreshing simplicity –*** cutting complexity by investing in what matters, and getting results faster; (iii) ***collective entrepreneurship –*** empowering our employees to act like they own our business, while embracing the power of inclusion and teamwork; (iv) ***safety obsession –*** living our steadfast belief that a safe workplace is a profitable workplace; and, (v) ***unshakable integrity –*** doing what’s right for our customers, colleagues, and communities – always.

Additionally, our Corporate Responsibility commitment focuses on three key principles – inspired people, a shared planet, and an evolved portfolio – in an effort to achieve, among other goals, increased diversity and inclusion in our global workforce, increased sustainability of our products, and becoming carbon positive. We call this responsible chemistry – it is rooted in who we are, and we expect that our Corporate Responsibility commitment will drive sustainable, long-term earnings growth.

### Recent Developments

### Accounts Receivable Securitization Facility

In July 2019, we, through a wholly-owned special purpose entity, entered into an accounts receivable securitization facility (“Securitization Facility”) to enhance our liquidity. The net borrowings under the Securitization Facility since July 2019 amounted to $122 million, which remained outstanding as of September 30, 2019. The proceeds were used to pay down our outstanding revolving loan balance.

### 2019 Restructuring Program

In an effort to better align our cost structure with market opportunities we recorded severance charges of $17 million during the three months ended September 30, 2019. This charge includes $2 million related to our exit of the Methylamines and Methylamides business as discussed below. Impacted employees are subject to our customary involuntary termination benefits. The majority of the employees will separate from the Company during the fourth quarter of 2019.

Also in the third quarter of 2019, we announced plans to exit the Methylamines and Methylamides business at our Belle, West Virginia manufacturing plant. As a result, for the three and nine months ended September 30, 2019 we recorded charges of approximately $10 million for property, plant, and equipment and $2 million for other asset impairment charges. As of September 30, 2019, we incurred, in the aggregate, $14 million in restructuring charges related to these activities, including asset-related charges. We expect to incur additional charges of $22 million for property, plant, and equipment and other assets through the remainder of 2019, and additional restructuring charges, including decommissioning and dismantling, of approximately $11 million through 2020, all of which relates to Chemical Solutions.

### Results of Operations and Business Highlights

### Results of Operations

The following table sets forth our results of operations for the three and nine months ended September 30, 2019 and 2018.

*(Dollars in millions, except per share amounts)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,390 | $1,628 | $4,173 | $5,174 |
| Cost of goods sold | 1,096 | 1,151 | 3,260 | 3,603 |
| Gross profit | 294 | 477 | 913 | 1,571 |
| Selling, general, and administrative expense | 130 | 163 | 423 | 466 |
| Research and development expense | 20 | 20 | 61 | 61 |
| Restructuring, asset-related, and other charges | 34 | 12 | 49 | 32 |
| Total other operating expenses | 184 | 195 | 533 | 559 |
| Equity in earnings of affiliates | 9 | 10 | 25 | 32 |
| Interest expense, net | (53) | (47) | (156) | (148) |
| Loss on extinguishment of debt | — | — | — | (38) |
| Other income, net | 25 | 24 | 81 | 115 |
| **Income before income taxes** | 91 | 269 | 330 | 973 |
| Provision for (benefit from) income taxes | 15 | (6) | 65 | 119 |
| **Net income** | 76 | 275 | 265 | 854 |
| Less: Net income attributable to non-controlling interests | — | — | — | 1 |
| **Net income attributable to Chemours** | $76 | $275 | $265 | $853 |
| **Per share data** |  |  |  |  |
| Basic earnings per share of common stock | $0.46 | $1.56 | $1.60 | $4.77 |
| Diluted earnings per share of common stock | 0.46 | 1.51 | 1.58 | 4.62 |

45

### Net Sales

The following table sets forth the impact of price, volume, and currency on our net sales for the three and nine months ended September 30, 2019, compared with the same periods in 2018.

| Change in net sales from prior period | Three Months Ended September 30, 2019 | Nine Months Ended September 30, 2019 |
| --- | ---: | ---: |
| Price | (3)% | (1)% |
| Volume | (11)% | (17)% |
| Currency | (1)% | (1)% |
| **Total change in net sales** | (15)% | (19)% |

Our net sales decreased by $238 million (or 15%) to $1.4 billion for the three months ended September 30, 2019, compared with net sales of $1.6 billion for the same period in 2018. The components of the decrease in our net sales by segment for the three months ended September 30, 2019 were as follows: in our Fluoroproducts segment, volume was down 2%, price declined 4%, and unfavorable currency movements added a 1% headwind to segment net sales; in our Chemical Solutions segment, volume was up 1% and price declined 11%; and, in our Titanium Technologies segment, volume and price were down 20% and 2%, respectively.

Our net sales decreased by $1.0 billion (or 19%) to $4.2 billion for the nine months ended September 30, 2019, compared with net sales of $5.2 billion for the same period in 2018. The components of the decrease in our net sales by segment for the nine months ended September 30, 2019 were as follows: in our Fluoroproducts segment, volume was down 5%, price declined 2%, and unfavorable currency movements added a 1% headwind to segment net sales; in our Chemical Solutions segment, volume and price decline by 8% and 3%, respectively; and, in our Titanium Technologies segment, volume was down 30%, while unfavorable currency movements added a 1% headwind to segment net sales.

The drivers of these changes for each of our segments are discussed further under the heading “Segment Reviews,” which follows our “Results of Operations and Business Highlights” in this *MD&A.*

### Cost of Goods Sold

Our cost of goods sold (“COGS”) decreased by $55 million (or 5%) and $343 million (or 10%) to $1.1 billion and $3.3 billion for the three and nine months ended September 30, 2019, respectively, compared with COGS of $1.2 billion and $3.6 billion for the same periods in 2018. The decreases in our COGS for the three and nine months ended September 30, 2019 were primarily attributable to lower net sales volumes, which were partially offset by the impacts of operational headwinds.

### Selling, General, and Administrative Expense

Our selling, general, and administrative (“SG&A”) expense decreased by $33 million (or 20%) to $130 million for the three months ended September 30, 2019, compared with SG&A expense of $163 million for the same period in 2018. The decrease in our SG&A expense for the three months ended September 30, 2019 was primarily attributable to lower costs for certain legal matters.

Our SG&A expense decreased by $43 million (or 9%) to $423 million for the nine months ended September 30, 2019, compared with SG&A expense of $466 million for the same period in 2018. The decrease in our SG&A expense for the nine months ended September 30, 2019 was primarily attributable to lower performance-related compensation and costs incurred for our 2018 debt transactions that were not repeated in 2019, and lower costs for certain legal matters. These decreases were partially offset by increased legal costs accrued during the first quarter of 2019 in connection with the approved final Consent Order to settle certain litigation and other matters at our Fayetteville, North Carolina facility.

### Research and Development Expense

Our research and development expense was unchanged at $20 million and $61 million, and $20 million and $61 million for the three and nine months ended September 30, 2019 and 2018, respectively.

### Restructuring, Asset-Related, and Other Charges

Our restructuring, asset-related, and other charges increased by $22 million (or greater than 100%) and $17 million (or 53%) to $34 million and $49 million for the three and nine months ended September 30, 2019, respectively, compared with restructuring, asset-related, and other charges of $12 million and $32 million for the same periods in 2018.

Our restructuring, asset-related, and other charges for the three months ended September 30, 2019 were primarily composed of charges related to our 2019 Restructuring Program, including our plans to exit the Methylamines and Methylamides business at the Belle, WV manufacturing plant, both announced in the third quarter of 2019.

Our restructuring, asset-related, and other charges for the nine months ended September 30, 2019 primarily consisted of the aforementioned three months ended September 30, 2019 charges plus continuing decommissioning and dismantling-related charges associated with the demolition and removal of certain unused buildings at our Chambers Works site in Deepwater, NJ and the Reactive Metals Solutions business in Niagara Falls, NY.

Our restructuring, asset-related, and other charges for the three and nine months ended September 30, 2018 were primarily attributable to continued progress on our business process and information technology outsourcing efforts, as well as additional severance accruals under our 2017 restructuring program.

### Equity in Earnings of Affiliates

Our equity in earnings of affiliates decreased by $1 million (or 10%) and $7 million (or 22%) to $9 million and $25 million for the three and nine months ended September 30, 2019, respectively, compared with equity in earnings of affiliates of $10 million and $32 million for the same periods in 2018.

The decrease in our equity in earnings of affiliates for the three months ended September 30, 2019 was primarily attributable to global automotive market softness for our investees in the Fluoroproducts segment.

The decrease in our equity in earnings of affiliates for the nine months ended September 30, 2019 was primarily attributable to global semiconductor and automotive market softness for our investees in the Fluoroproducts segment.

### Interest Expense, Net

Our interest expense, net increased by $6 million (or 13%) and $8 million (or 5%) to $53 million and $156 million for the three and nine months ended September 30, 2019, respectively, compared with interest expense, net of $47 million and $148 million for the same periods in 2018.

The increase in our interest expense, net for the three months ended September 30, 2019 was primarily attributable to lower amounts of interest income and capitalized interest due to lower cash and cash equivalents balances and the completion or stoppage of certain of our large-scale construction projects, respectively.

The increase in our interest expense, net for the nine months ended September 30, 2019 was primarily attributable to lower amounts of interest income and capitalized interest due to the aforementioned reasons, which more than offset the impact of any reduced interest costs resulting from our 2018 debt transactions.

### Loss on Extinguishment of Debt

We incurred a loss on extinguishment of debt of $38 million for the nine months ended September 30, 2018 in connection with our 2018 debt transactions.

### Other Income, Net

Our other income, net increased by $1 million (or 4%) and decreased $34 million (or 30%) to $25 million and $81 million for the three and nine months ended September 30, 2019, respectively, compared with other income, net of $24 million and $115 million for the same periods in 2018.

The increase in our other income, net for the three months ended September 30, 2019 was primarily attributable to recognition of the previously deferred non-cash gain of $9 million, associated with the sale of the Repauno site in Gibbstown, NJ. The gain had been deferred until certain environmental obligations had been fulfilled. This was offset by lower European Union (“EU”) fluorinated greenhouse gas (“F-gas”) quota authorization sales.

The decrease in our other income, net for the nine months ended September 30, 2019 was primarily attributable to a $42 million gain on our sale of land in Linden, New Jersey during the first quarter of 2018, which was not repeated in 2019. This decrease was partially offset by the recognition of the previously deferred non-cash gain of $9 million, associated with the sale of the Repauno site in Gibbstown, NJ.

### Provision for Income Taxes

Our provisions for income taxes were $15 million and $65 million for the three and nine months ended September 30, 2019, which represented effective tax rates of 16% and 20%, respectively, compared with benefit from and provision for income taxes of $6 million and $119 million for the same periods in 2018, which represented effective tax rates of approximately negative 2% and 12%, respectively. The change in the Company’s effective tax rate for the three months ended September 30, 2019 was primarily attributable to $5 million of additional income tax expense on the revaluation of certain deferred tax assets and liabilities as result of the increased corporate tax rate for a certain foreign subsidiary, $3 million of lower income tax benefits related to windfalls on its share-based payments, reduced profitability and the geographic mix of its earnings. The change in the Company’s effective tax rate for the three months ended September 30, 2018 was primarily attributable to $17 million in income tax benefits related to the reversal of the valuation allowance on carryforward foreign tax credits, $14 million in income tax benefits related to the filing of the Company’s 2017 U.S. tax return and the associated adjustments on the revaluation of certain deferred tax assets and liabilities as a result of the reduced corporate tax rate, and the Company’s geographic mix of earnings.

The change in the Company’s effective tax rate for the nine months ended September 30, 2019 were primarily attributable to $5 million of additional income tax expense on the revaluation of certain deferred tax assets and liabilities as result of the increased corporate tax rate for a certain foreign subsidiary, $8 million of additional income tax expense associated with the recognition of a valuation allowance on the deferred tax assets of a certain foreign subsidiary, $8 million of lower income tax benefits related to windfalls on its share-based payments, reduced profitability and the geographic mix of its earnings. The change in the Company’s effective tax rate for the nine months ended September 30, 2018 was primarily attributable to $17 million in income tax benefits related to the reversal of the valuation allowance on carryforward foreign tax credits, $14 million in income tax benefits related to the filing of the Company’s 2017 U.S. tax return and the associated adjustments on the revaluation of certain deferred tax assets and liabilities as a result of the reduced corporate tax rate, and the Company’s geographic mix of earnings.

### Segment Reviews

Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is the primary measure of segment performance used by our Chief Operating Decision Maker (“CODM”) and is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represents the component of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of assets and businesses; and,
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

A reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three and nine months ended September 30, 2019 and 2018 is included in the “Non-GAAP Financial Measures” section of this *MD&A.*

The following table sets forth our Adjusted EBITDA by segment for the three and nine months ended September 30, 2019 and 2018.

*(Dollars in millions)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Fluoroproducts | $122 | $182 | $461 | $619 |
| Chemical Solutions | 23 | 24 | 55 | 50 |
| Titanium Technologies | 137 | 268 | 390 | 856 |
| Corporate and Other | (34) | (39) | (113) | (126) |
| **Total Adjusted EBITDA** | $248 | $435 | $793 | $1,399 |

48

### Fluoroproducts

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Fluoroproducts segment for the three and nine months ended September 30, 2019 and 2018.

*(Dollars in millions)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Segment net sales | $636 | $682 | $2,034 | $2,213 |
| Adjusted EBITDA | 122 | 182 | 461 | 619 |
| Adjusted EBITDA margin | 19% | 27% | 23% | 28% |

The following table sets forth the impacts of price, volume, and currency on our Fluoroproducts segment’s net sales for the three and nine months ended September 30, 2019, compared with the same periods in 2018.

| Change in segment net sales from prior period | Three Months Ended September 30, 2019 | Nine Months Ended September 30, 2019 |
| --- | ---: | ---: |
| Price | (4)% | (2)% |
| Volume | (2)% | (5)% |
| Currency | (1)% | (1)% |
| **Total change in segment net sales** | (7)% | (8)% |

49

#### Segment Net Sales

Our Fluoroproducts segment’s net sales decreased by $46 million (or 7%) to $636 million for the three months ended September 30, 2019, compared with segment net sales of $682 million for the same period in 2018. The decrease in segment net sales for the three months ended September 30, 2019 was driven by decreases in price and volumes of 4% and 2%, respectively. Illegal imports of legacy hydrofluorocarbon (“HFC”) refrigerants into the EU in violation of the region’s F-gas regulations, impacted both volume and price during the quarter; and, volumes also declined due to lower demand for our legacy base refrigerants and polymers due to softness in the global automotive and electronics markets. These decreases were partially offset by volume increases from the continued adoption of OpteonTM products in mobile applications and the positive impact of high-grade Fluoropolymer sales. Unfavorable currency movements added a 1% headwind to the segment’s net sales during the quarter.

Our Fluoroproducts segment’s net sales decreased by $179 million (or 8%) to $2.0 billion for the nine months ended September 30, 2019, compared with segment net sales of $2.2 billion for the same period in 2018. The decrease in segment net sales for the nine months ended September 30, 2019 was primarily attributable to decreases in price and volume of 2% and 5%, respectively. Illegal imports of legacy hydrofluorocarbon (“HFC”) refrigerants into the EU in violation of the region’s F-gas regulations impacted both volume and price during the quarter; and, volumes also declined due to lower demand for our legacy base refrigerants and polymers due to softness in the global automotive and electronics markets. These decreases were partially offset by volume increases from the continued adoption of OpteonTM products in mobile applications and the positive impact of high-grade Fluoropolymer sales. Unfavorable currency movements added a 1% headwind to the segment’s net sales during the nine months ended September 30, 2019.

#### Adjusted EBITDA and Adjusted EBITDA Margin

For the three months ended September 30, 2019, segment Adjusted EBITDA decreased by $60 million (or 33%) to $122 million and Adjusted EBITDA margin decreased by approximately 800 basis points to 19%, compared with segment Adjusted EBITDA of $182 million and Adjusted EBITDA margin of 27% for the same period in 2018. These declines primarily resulted from the aforementioned impacts of illegal imports and other volume and price impacts along with operational headwinds, as well as lower F-Gas quota sales. These declines were partially offset by lower cost of goods sold from increased production at our new Corpus Christi OpteonTM site

For the nine months ended September 30, 2019, segment Adjusted EBITDA decreased by $158 million (or 26%) to $461 million and Adjusted EBITDA margin decreased by approximately 500 basis points to 23%, compared with segment Adjusted EBITDA of $619 million and Adjusted EBITDA margin of 28% for the same period in 2018. These decreases were primarily attributable to the aforementioned decreases in volume, price, and unfavorable currency movements. Additionally, we experienced increased costs for the nine months ended September 2019 due to the start-up of our new OpteonTM refrigerants facility in Corpus Christi, Texas, and unplanned outages at some facilities.

### Chemical Solutions

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Chemical Solutions segment for the three and nine months ended September 30, 2019 and 2018.

*(Dollars in millions)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Segment net sales | $140 | $155 | $404 | $453 |
| Adjusted EBITDA | 23 | 24 | 55 | 50 |
| Adjusted EBITDA margin | 17% | 16% | 14% | 11% |

The following table sets forth the impacts of price, volume, and currency on our Chemical Solutions segment’s net sales for the three and nine months ended September 30, 2019, compared with the same periods in 2018.

| Change in segment net sales from prior period | Three Months Ended September 30, 2019 | Nine Months Ended September 30, 2019 |
| --- | ---: | ---: |
| Price | (11)% | (3)% |
| Volume | 1% | (8)% |
| Currency | —% | —% |
| **Total change in segment net sales** | (10)% | (11)% |

51

#### Segment Net Sales

Our Chemical Solutions segment’s net sales decreased by $15 million (or 10%) to $140 million for the three months ended September 30, 2019, compared with segment net sales of $155 million for the same period in 2018. The decrease in segment net sales for the three months ended September 30, 2019 was primarily attributable to lower prices, primarily in Performance Chemicals and Intermediates, mainly driven by mix and raw material cost pass-throughs as stipulated in certain contracts.

Our Chemical Solutions segment’s net sales decreased by $49 million (or 11%) to $404 million for the nine months ended September 30, 2019, compared with segment net sales of $453 million for the same period in 2018. The decrease in segment net sales for the nine months ended September 30, 2019 was primarily attributable to operational issues at a key customer mine in Mining Solutions, lower prices for certain Performance Chemicals and Intermediates products, mainly driven by mix and raw material cost pass-throughs as stipulated in certain contracts.

#### Adjusted EBITDA and Adjusted EBITDA Margin

For the three months ended September 30, 2019, segment Adjusted EBITDA decreased by $1 million (or 4%) to $23 million, while Adjusted EBITDA margin improved to 17% compared with segment Adjusted EBITDA of $24 million and Adjusted EBITDA margin of 16% for the same period in 2018. The impact of lower sales was largely offset by increased license income and lower cost of goods sold.

For the nine months ended September 30, 2019, segment Adjusted EBITDA increased by $5 million (or 11%) to $55 million and Adjusted EBITDA margin increased by approximately 300 basis points to 14%, compared with segment Adjusted EBITDA of $50 million and Adjusted EBITDA margin of 11% for the same period in 2018. These increases were attributable to increased license income, lower costs associated with certain capital projects and lower cost of goods sold, offset by the aforementioned decreases in net sales due to price and volume.

### Titanium Technologies

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Titanium Technologies segment for the three and nine months ended September 30, 2019 and 2018.

*(Dollars in millions)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Segment net sales | $614 | $791 | $1,735 | $2,508 |
| Adjusted EBITDA | 137 | 268 | 390 | 856 |
| Adjusted EBITDA margin | 22% | 34% | 22% | 34% |

The following table sets forth the impacts of price, volume, and currency on our Titanium Technologies segment’s net sales for the three and nine months ended September 30, 2019, compared with the same periods in 2018.

| Change in segment net sales from prior period | Three Months Ended September 30, 2019 | Nine Months Ended September 30, 2019 |
| --- | ---: | ---: |
| Price | (2)% | —% |
| Volume | (20)% | (30)% |
| Currency | —% | (1)% |
| **Total change in segment net sales** | (22)% | (31)% |

53

#### Segment Net Sales

Our Titanium Technologies segment’s net sales decreased by $177 million (or 22%) to $614 million for the three months ended September 30, 2019, compared with segment net sales of $791 million for the same period in 2018. The decrease in segment net sales for the three months ended September 30, 2019 was attributable to a 20% decrease in volume, primarily due to lower volumes of Ti-PureTM titanium dioxide. Price declined slightly primarily due to customer, regional and channel mix, but remained largely stable as a result of our Ti-PureTM Value Stabilization (“TVS”) strategy.

Our Titanium Technologies segment’s net sales decreased by $772 million (or 31%) to $1.7 billion for the nine months ended September 30, 2019, compared with segment net sales of $2.5 billion for the same period in 2018. The decrease in segment net sales for the nine months ended September 30, 2019 was attributable to a 30% decrease in volume, primarily due to lower volumes of Ti-PureTM titanium dioxide, and a 1% headwind from unfavorable currency movements. Price remained stable as a result of the implementation of our TVS strategy.

#### Adjusted EBITDA and Adjusted EBITDA Margin

For the three months ended September 30, 2019, segment Adjusted EBITDA decreased by $131 million (or 49%) to $137 million and Adjusted EBITDA margin decreased by approximately 1,200 basis points to 22%, compared with segment Adjusted EBITDA of $268 million and Adjusted EBITDA margin of 34% for the same period in 2018.

For the nine months ended September 30, 2019, segment Adjusted EBITDA decreased by $466 million (or 54%) to $390 million and Adjusted EBITDA margin decreased by approximately 1,200 basis points to 22%, compared with segment Adjusted EBITDA of $856 million and Adjusted EBITDA margin of 34% for the same period in 2018.

These decreases were primarily attributable to the aforementioned decreases in volume and, as well as margin compression due to reduced production rates as we adjust the utilization of our manufacturing units to match the reduced customer demand.

### Corporate and Other

Corporate and Other costs decreased by $5 million (or 13%) and $13 million (or 10%) to $34 million and $113 million for the three and nine months ended September 30, 2019, respectively, compared with Corporate and Other costs of $39 million and $126 million for the same periods in 2018.

The decrease in our Corporate and Other costs for the three months ended September 30, 2019 was primarily attributable to lower performance-related compensation and other general administrative costs, partially offset by increased costs related to business process improvement efforts.

The decrease in our Corporate and Other costs for the nine months ended September 30, 2019 was primarily attributable to lower costs for certain legacy environmental and legal matters, as well as lower performance-related compensation, partially offset by increased costs related to business process improvement efforts.

### 2019 Outlook

Our 2019 results will be driven by the following expectations: (i) 2019 volume for our Titanium Technologies segment will be below 2018 volume levels as we execute our TVS strategy; (ii) there will be continued transition to OpteonTM refrigerants in our Fluoroproducts segment, which will be offset by the impacts of illegal imports of legacy HFC refrigerants into the EU in violation of the region’s F-gas regulations; and, (iii) there will be continued demand for Mining Solutions products in our Chemical Solutions segment. We expect that our capital expenditures will be approximately $500 million. Our outlook for 2019 reflects our current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. These expectations are subject to numerous risks, including, but not limited to, those described in *Item 1A – Risk Factors* contained in our Annual Report on Form 10-K for the year ended December 31, 2018.

### Liquidity and Capital Resources

Our primary sources of liquidity are cash generated from operations, available cash, receivables securitization, and borrowings under our debt financing arrangements, which are described in further detail in “Note 17 – Debt” to the *Interim Consolidated Financial Statements* and “Note 19 – Debt” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018. We believe these sources are sufficient to fund our planned operations and to meet our interest, dividend, and contractual obligations. Our financial policy seeks to: (i) selectively invest in organic and inorganic growth to enhance our portfolio, including certain strategic capital investments; (ii) return cash to shareholders through dividends and share repurchases; and, (iii) maintain appropriate leverage by using free cash flows to repay outstanding borrowings. Subject to approval by our board of directors, we may raise additional capital or borrowings from time to time, or seek to refinance our existing debt. There can be no assurances that future capital or borrowings will be available to us, and the cost and availability of new capital or borrowings could be materially impacted by market conditions. Further, the decision to refinance our existing debt is based on a number of factors, including general market conditions and our ability to refinance on attractive terms at any given point in time. Any attempts to raise additional capital or borrowings or refinance our existing debt could cause us to incur significant charges. Such charges could have a material impact on our financial position, results of operations, or cash flows.

Our operating cash flow generation is driven by, among other things, the general global economic conditions at any point in time and their resulting impact on demand for our products, raw materials and energy prices, and industry-specific issues, such as production capacity and utilization. We have generated strong operating cash flows through various industry and economic cycles, evidencing the operating strength of our businesses.

We anticipate making significant payments for interest, capital expenditures, environmental remediation costs and investments, dividends, and other actions over the next 12 months, which we expect to fund through cash generated from operations, available cash, receivables securitization, and borrowings. We further anticipate that our operations and existing debt financing arrangements will provide us with sufficient liquidity over the next 12 months. The availability under our revolving credit facility is subject to the last 12 months of consolidated EBITDA, as defined in our amended and restated credit agreement, which is discussed further in in “Note 17 – Debt” to the *Interim Consolidated Financial Statements* and “Note 19 – Debt” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018.

At September 30, 2019, we had total cash and cash equivalents of $694 million, of which, $551 million was held by our foreign subsidiaries. All of the cash and cash equivalents held by our foreign subsidiaries is readily convertible into currencies used in our operations, including the U.S. dollar. The cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At September 30, 2019, management believed that sufficient liquidity was available in the U.S., which includes borrowing capacity under our revolving credit facility, and it is our intention to indefinitely reinvest the historical pre-2018 earnings of our foreign subsidiaries. Beginning in 2018, management asserts that only certain foreign subsidiaries are indefinitely reinvested. See “Note 9 – Income Taxes” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018 for further information related to our income tax positions.

In July 2019, we repaid $150 million of our revolving loan borrowings using cash from the Securitization Facility and available cash.

### Cash Flows

The following table sets forth a summary of the net cash provided by (used for) our operating, investing, and financing activities for the nine months ended September 30, 2019 and 2018.

*(Dollars in millions)*

|  | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Cash provided by operating activities | $250 | $881 |
| Cash used for investing activities | (387) | (327) |
| Cash used for financing activities | (360) | (823) |

#### Operating Activities

We received $250 and $881 million in cash flows from our operating activities during the nine months ended September 30, 2019 and 2018, respectively. The decrease in cash flows from our operating activities for the nine months ended September 30, 2019 was primarily attributable to a decrease in our net income, as well as an increase in our net cash outflows for working capital items, primarily due to payments on our accounts payable and certain other accrued liabilities.

#### Investing Activities

We used $387 million and $327 million in cash flows for our investing activities during the nine months ended September 30, 2019 and 2018, respectively. Our investing cash outflows during the nine months ended September 30, 2019 were primarily attributable to $385 in payments for purchases of property, plant, and equipment.

For the nine months ended September 30, 2018, our investing cash outflows were primarily attributable to purchases of property, plant, and equipment for $344 million, as well as $37 million in total cash consideration payments for the acquisition of ICOR International, Inc. in April 2018. These cash outflows were somewhat offset by $46 million in net proceeds received from the sales of assets and businesses, primarily attributable to the sale of our Linden, New Jersey site in March 2018 for $39 million, and $8 million in net foreign exchange contract settlements.

#### Financing Activities

We used $360 million and $823 million in cash flows for our financing activities during the nine months ended September 30, 2019 and 2018, respectively. Our financing cash outflows during the nine months ended September 30, 2019 were primarily attributable to the following: $322 million in purchases of our issued and outstanding common stock under our share repurchase program in connection with our capital allocation activities; $124 million in payments for cash dividends; and, $30 million in payments for withholding taxes on certain of our vested stock-based compensation awards. We also drew $150 million on our revolving credit facility for general corporate purposes. We subsequently repaid the revolver borrowing in full, primarily using the $125 million proceeds from the Securitization Facility, as well as available cash. The Securitization Facility is further described in “Note 17 – Debt” to the *Interim Consolidated Financial Statements.*

Our financing cash outflows during the nine months ended September 30, 2018 were primarily attributable to debt repayments of $675 million and debt extinguishment payments of $29 million for “make-whole” and early prepayment premiums in connection with our debt transactions during the second quarter (discussed further under the heading “Credit Facilities and Notes” within this MD&A). Additionally, we made cash payments totaling $520 million for the repurchase of approximately 10.9 million shares of our issued and outstanding common stock under our share repurchase programs, and paid dividends amounting to $106 million during the nine months then-ended. These cash outflows were somewhat offset by $520 million in net proceeds received from the issuance of our euro-denominated 4.000% senior unsecured notes due May 2026 (2026 Euro Notes) in June 2018.

### Current Assets

The following table sets forth the components of our current assets at September 30, 2019 and December 31, 2018.

*(Dollars in millions)*

|  | September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Cash and cash equivalents | $694 | $1,201 |
| Accounts and notes receivable, net | 832 | 861 |
| Inventories | 1,223 | 1,147 |
| Prepaid expenses and other | 78 | 84 |
| **Total current assets** | $2,827 | $3,293 |

Our accounts and notes receivable, net decreased by $29 million (or 3%) to $832 million at September 30, 2019, compared with accounts and notes receivable, net of $861 million at December 31, 2018. The decrease in our accounts and notes receivable, net at September 30, 2019 was primarily attributable to the timing of payments from our customers.

Our inventories increased by $76 million (or 7%) to $1.2 billion at September 30, 2019, compared with inventories of $1.1 billion at December 31, 2018. The increase in our inventories at September 30, 2019 was primarily attributable to an increase in our raw materials, stores, and supplies inventories due to the strategic acquisition of ore in our Titanium Technologies segment.

Our prepaid expenses and other assets decreased by $6 million (or 7%) to $78 million at September 30, 2019, compared with prepaid expenses and other assets of $84 million at December 31, 2018. The decrease in our prepaid expenses and other assets at September 30, 2019 was primarily attributable to a decrease in prepaid income tax balances, which was partially offset by prepaid insurance premiums.

### Current Liabilities

The following table sets forth the components of our current liabilities at September 30, 2019 and December 31, 2018.

*(Dollars in millions)*

|  | September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Accounts payable | $948 | $1,137 |
| Short-term and current maturities of long-term debt | 149 | 13 |
| Other accrued liabilities | 546 | 559 |
| **Total current liabilities** | $1,643 | $1,709 |

Our accounts payable decreased by $189 million (or 17%) to $948 million at September 30, 2019, compared with accounts payable of $1.1 billion at December 31, 2018. The decrease in our accounts payable at September 30, 2019 was primarily attributable to the timing of payments to our vendors.

Our short-term and current maturities of long-term debt increased by $136 million (or greater than 100%) to $149 million at September 30, 2019, compared with current maturities of long-term debt of $13 million at December 31, 2018. The increase in our short-term and current maturities of long-term debt was primarily attributable to $122 million for the Securitization Facility, $9 for financed insurance premiums, and $5 for the current portion of finance lease liability.

Our other accrued liabilities decreased by $13 million (or 2%) to $546 million at September 30, 2019, compared with other accrued liabilities of $559 million at December 31, 2018. The decrease in our other accrued liabilities at September 30, 2019 was primarily attributable to lower accrued compensation and employee-related costs, and decreases in accrued litigation costs. These decreases were somewhat offset by our recognition of an operating lease liability in connection with our adoption of the new leasing standard on January 1, 2019, and an increase in accrued interest.

### Credit Facilities and Notes

See “Note 17 – Debt” to the *Interim Consolidated Financial Statements* and “Note 19 – Debt” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018 for a discussion of our credit facilities and notes.

### Supplier Financing

We maintain global paying services agreements with several financial institutions. Under these agreements, the financial institutions act as our paying agents with respect to accounts payable due to our suppliers who elect to participate in the program. The agreements allow our suppliers to sell their receivables to one of the participating financial institutions at the discretion of both parties on terms that are negotiated between the supplier and the respective financial institution. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers’ decisions to sell their receivables under this program. At September 30, 2019 and December 31, 2018, the total payment instructions from us amounted to $116 million and $210 million, respectively. Pursuant to their agreement with one of the financial institutions, certain suppliers may elect to be paid early at their discretion. The available capacity under these programs can vary based on the number of investors and/or financial institutions participating in these programs at any point in time.

### Contractual Obligations

Our contractual obligations at September 30, 2019 did not significantly change from the contractual obligations previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

### Off Balance Sheet Arrangements

Historically, we have not made significant payments to satisfy guarantee obligations; however, we believe we have the financial resources to satisfy these guarantees in the event required.

### Critical Accounting Policies and Estimates

Our significant accounting policies are described in our *MD&A* and “Note 3 – Summary of Significant Accounting Policies” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no material changes to these critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, except as described below and in “Note 2 – Recent Accounting Pronouncements” to the *Interim Consolidated Financial Statements.*

### Netherlands Pension Plan

In accordance with the planned restructuring of our Netherlands pension plan (“Plan”), $935 million of annuity contracts were purchased by the Plan in July 2019 in an amount sufficient to pay off the pension benefits of the Plan’s vested retirees and inactive participants. The Dutch National Bank (“DNB”) responded on October 10, 2019 with a letter of non-objection to our planned transaction as a partial settlement of the Plan. Having received this, the insurance company is in the process of assuming direct and irrevocable responsibility for the payment of pension benefits to the Plan’s vested retirees and inactive participants. The irrevocable transfer of risk will then trigger a partial settlement of the Plan, which we expect will result in a non-cash settlement charge between $350 million to $400 million during the fourth quarter of 2019, most of which is already recorded as a component of our accumulated other comprehensive loss. The purchase of these annuity contracts was fully-funded by the Plan’s investment trust.

### Goodwill

The excess of the purchase price over the estimated fair value of the net assets acquired in a business combination, including any identified intangible assets, is recorded as goodwill. Chemours tests its goodwill for impairment at least annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Goodwill is evaluated for impairment at the reporting unit level, which is defined as an operating segment, or one level below an operating segment. A reporting unit is the level at which discrete financial information is available and reviewed by business management on a regular basis. An impairment exists when the carrying value of a reporting unit exceeds its fair value. The amount of impairment loss recognized in the consolidated statements of operations is equal to the excess of a reporting unit’s carrying value over its fair value, which is limited to the total amount of goodwill allocated to the reporting unit.

During the third quarter of 2019, due to several factors including sustained declines in the Company’s share price, regulatory developments, and declines in actual and planned earnings compared with expectations, it was determined that an interim test of goodwill for impairment was necessary as of August 31, 2019 for our Fluorochemicals and Fluoropolymers reporting units.

The fair value of each reporting unit was determined by using a combination of income-based and market-based valuation techniques. The results of these valuations were each weighted 50%. These valuation models incorporated a number of assumptions and judgments surrounding general market and economic conditions, short and long-term revenue growth rates, gross margins and prospective financial information surrounding future reporting unit cash flows. Projections are based on internal forecasts of future business performance and are based on growth assumptions which exclude business growth opportunities not yet fully realized. Discount rate and market multiple assumptions were determined based on relevant peer companies in the chemicals sector, and for the Fluoropolymers reporting unit were 9.75% and 6.2 times Adjusted EBITDA, respectively.

As of August 31, 2019, the estimated fair value of the Fluoropolymers reporting unit was 16% higher than its carrying value. Fluoropolymers has $56 million of goodwill. Changing the weighting of the market and income approaches used for Fluoropolymers could have reduced the excess of estimated fair value over carrying value to 14%. Assuming all other factors remain the same, a 200-basis point increase in the discount rate would decrease the excess of estimated fair value over carrying value to 4%; a 1% decrease in the long-term growth rate would decrease the excess of estimated fair value over carrying value to 11%; and a 15% decrease in the market multiple assumption would decrease the excess of estimated fair value over carrying value to 7%. Under each of these sensitivity scenarios, the Fluoropolymers reporting unit's fair value exceeded its carrying value.

As of August 31, 2019, the estimated fair value of the Fluorochemicals reporting unit was more than 300% higher than its carrying value.

No adjustments to the carrying value of goodwill were necessary.

### Recent Accounting Pronouncements

See “Note 2 – Recent Accounting Pronouncements” to the *Interim Consolidated Financial Statements* for a discussion about recent accounting pronouncements.

### Environmental Matters

Consistent with our values and our *Environment, Health, Safety, and Corporate Responsibility* policy, we are committed to preventing releases to the environment at our manufacturing sites to keep our people and communities safe, and to be good stewards of the environment. We are also subject to environmental laws and regulations relating to the protection of the environment. We believe that, as a general matter, our policies, standards, and procedures are properly designed to prevent unreasonable risk of harm to people and the environment, and that our handling, manufacture, use, and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.

### Environmental Remediation

In large part, because of past operations, operations of predecessor companies, or past disposal practices, we, like many other similar companies, have clean-up responsibilities and associated remediation costs, and are subject to claims by other parties, including claims for matters that are liabilities of DuPont and its subsidiaries that we may be required to indemnify pursuant to the separation-related agreements executed prior to our separation from DuPont.

Our environmental reserve includes estimated costs, including certain accruable costs associated with on-site capital projects, related to a number of sites for which it is probable that environmental remediation will be required, whether or not subject to enforcement activities, as well as those obligations that result from environmental laws such as the Comprehensive Environmental Response Compensation and Liability Act (“CERCLA,” often referred to as “Superfund”), the Resource Conservation and Recovery Act (“RCRA”), and similar federal, state, local, and foreign laws. These laws require certain investigative, remediation, and restoration activities at sites where we conduct or once conducted operations or at sites where our generated waste was disposed. At September 30, 2019 and December 31, 2018, our consolidated balance sheets included environmental remediation liabilities of $239 million and $226 million, respectively, relating to these matters, which, as discussed in further detail below, included $29 million and $10 million for our Fayetteville, North Carolina facility at September 30, 2019 and December 31, 2018, respectively. In management’s opinion, our environmental remediation liabilities are appropriate based on existing facts and circumstances.

As remediation efforts progress, sites move from the investigation phase (“Investigation”) to the active clean-up phase (“Active Remediation”), and as construction is completed at Active Remediation sites, those sites move to the operation, maintenance, and monitoring (“OM&M”), or closure phase. As final clean-up activities for some significant sites are completed over the next several years, we expect our annual expenses related to these active sites to decline over time. The time frame for a site to go through all phases of remediation (Investigation and Active Remediation) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, and diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties (“PRPs”). In addition, for claims that we may be required to indemnify DuPont pursuant to the separation-related agreements, we and DuPont may have limited available information for certain sites or are in the early stages of discussions with regulators. For these sites, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs, and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately $570 million above the amount accrued at September 30, 2019. In general, uncertainty is greatest and the range of potential liability is widest in the Investigation phase, narrowing over time as regulatory agencies approve site remedial plans. As a result, uncertainty is reduced, and sites ultimately move into OM&M, as needed. As more sites advance from Investigation to Active Remediation to OM&M or closure, the upper end of the range of potential liability is expected to decrease over time.

Some remediation sites will achieve site closure and will require no further action to protect people and the environment and comply with laws and regulations. At certain sites, we expect that there will continue to be some level of remediation activity due to ongoing OM&M of remedial systems. In addition, portfolio changes, such as an acquisition or divestiture, or notification as a PRP for a multi-party Superfund site, could result in additional remediation activity and potentially additional accrual.

Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position, results of operations, or cash flows for any given year, as such obligation can be satisfied or settled over many years.

### Significant Environmental Remediation Sites

While there are many remediation sites that contribute to our total accrued environmental remediation liabilities at September 30, 2019 and December 31, 2018, the following table sets forth the sites that are the most significant.

*(Dollars in millions)*

|  | September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Chambers Works, Deepwater, New Jersey | $20 | $18 |
| East Chicago, Indiana | 18 | 21 |
| Fayetteville Works, Fayetteville, North Carolina | 29 | 10 |
| Pompton Lakes, New Jersey | 43 | 45 |
| USS Lead, East Chicago, Indiana | 14 | 15 |
| All other sites | 115 | 117 |
| **Total accrued environmental remediation** | $239 | $226 |

59

The five sites listed above represented 52% and 48% of our total accrued environmental remediation liabilities at September 30, 2019 and December 31, 2018, respectively. For these five sites, we expect to spend, in the aggregate, $72 million over the next three years. For all other sites, we expect to spend $73 million over the next three years.

#### Chambers Works, Deepwater, New Jersey

The Chambers Works complex is located on the eastern shore of the Delaware River in Deepwater, Salem County, New Jersey. The site comprises the former Carneys Point Works in the northern area and the Chambers Works manufacturing area in the southern area. Site operations began in 1892 when the former Carneys Point smokeless gunpowder plant was constructed at the northern end of Carneys Point. Site operations began in the manufacturing area around 1914 and included the manufacture of dyes, aromatics, elastomers, chlorofluorocarbons, and tetraethyl lead. We continue to manufacture a variety of fluorochemicals and finished products at Chambers Works. In addition, three tenants operate processes at Chambers Works including steam/electricity generation, industrial gas production, and the manufacture of intermediate chemicals. As a result of over 100 years of continuous industrial activity, site soils and groundwater have been impacted by chemical releases.

In response to identified groundwater contamination, a groundwater interceptor well system (“IWS”) was installed in 1970, which was designed to contain contaminated groundwater and restrict off-site migration. Additional remediation is being completed under a federal RCRA Corrective Action permit. The site has been studied extensively over the years, and more than 25 remedial actions have been completed to date and engineering and institutional controls put in place to ensure protection of people and the environment. In the fourth quarter of 2017, a site perimeter sheet pile barrier intended to more efficiently contain groundwater was completed.

Remaining work beyond continued operation of the IWS and groundwater monitoring includes completion of various targeted studies on site and in adjacent water bodies to close investigation data gaps, as well as selection and implementation of final remedies under RCRA Corrective Action for various solid waste management units and areas of concern not yet addressed through interim measures.

#### East Chicago, Indiana

East Chicago is a former manufacturing facility we own in East Chicago, Lake County, Indiana. The approximate 440-acre site is bounded to the south by the east branch of the Grand Calumet River, to the east and north by residential and commercial areas, and to the west by industrial areas, including a former lead processing facility. The inorganic chemicals unit on site produced various chloride, ammonia, and zinc products and inorganic agricultural chemicals beginning in 1892 until 1986. Organic chemical manufacturing began in 1944, consisting primarily of chlorofluorocarbons production. Current operations, including support activities, now cover 28 acres of the site. The remaining business was sold to W.R. Grace Company (“Grace”) in early 2000, and Grace operates the unit as a tenant. Approximately 172 acres of the site were never developed and are managed by The Nature Conservancy for habitat preservation.

A comprehensive evaluation of soil and groundwater conditions at the site was performed as part of the RCRA Corrective Action process. Studies of historical site impacts began in 1983 in response to preliminary CERCLA actions undertaken by the U.S. Environmental Protection Agency (“EPA”). The EPA eventually issued an Administrative Order on Consent for the site in 1997. The order specified that remediation work be performed under RCRA Corrective Action authority. Work has proceeded under the RCRA Corrective Action process since that time.

Subsequent investigations included the preparation of initial environmental site assessments and multiple phases of investigation. In 2002, as an interim remedial measure, two 2,000-foot long permeable reactive barrier treatment walls were installed along the northern property boundary to address migration of chemicals in groundwater. Since that time, the investigation process has been completed and approved by the EPA, and the final remedy for the site was issued by the EPA in July 2018.

#### Fayetteville Works, Fayetteville, North Carolina

The Fayetteville Works facility is located 15 miles southeast of the City of Fayetteville in Cumberland and Bladen counties, North Carolina. The facility encompasses approximately 2,200 acres, which were purchased by DuPont in 1970, and are bounded to the east by the Cape Fear River and to the west by North Carolina Highway 87. Currently, the site manufactures plastic sheeting, fluorochemicals, and intermediates for plastics manufacturing. A former manufacturing area, which was sold in 1992, produced nylon strapping and elastomeric tape. DuPont sold its Butacite® and SentryGlas® manufacturing units to Kuraray America, Inc. in September 2014. In July 2015, upon our separation from DuPont, we became the owner of the Fayetteville Works land assets along with fluoromonomers, Nafion® membranes, and the related polymer processing aid manufacturing units. A polyvinyl fluoride resin manufacturing unit remained with DuPont.

Beginning in 1996, several stages of site investigation were conducted under NC DEQ oversight, as required by the facility's hazardous waste permit. In addition, the site has voluntarily agreed to agency requests for additional investigations of the potential release of “PFAS” (perfluoroalkyl and polyfluoroalkyl substances) beginning with “PFOA” (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) in 2006. As a result of detection of the polymerization processing aid hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid,” sometimes referred to as “GenX” or “C3 Dimer Acid”) in on-site groundwater wells during our investigations in 2017, the NC DEQ issued a Notice of Violation (“NOV”) on September 6, 2017 alleging violations of North Carolina water quality statutes and requiring further response. Since that time, and in response to three additional NOVs issued by NC DEQ, we have worked cooperatively with the agency to investigate and address releases of PFAS to on-site and off-site groundwater and surface water.

As discussed in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*, we and the NC DEQ have filed a final Consent Order that comprehensively addressed various issues, NOVs, and court filings made by the NC DEQ regarding our Fayetteville, North Carolina facility and resolved litigations filed by the NC DEQ and Cape Fear River Watch, a non-profit organization. Of the total estimated liability of $83 million accrued for this matter at September 30, 2019, $29 million is included within our overall environmental remediation liabilities, and is related to on-site groundwater and surface water conditions that require further study and clean-up action, and the estimated accruable costs associated with certain on-site capital projects under the final Consent Order.

#### Pompton Lakes, New Jersey

During the 20th century, blasting caps, fuses, and related materials were manufactured at Pompton Lakes, Passaic County, New Jersey. Operating activities at the site were ceased in the mid-1990s. The primary contaminants in the soil and sediments are lead and mercury. Groundwater contaminants include volatile organic compounds. Under the authority of the EPA and the New Jersey Department of Environmental Protection (“NJ DEP”), remedial actions at the site are focused on investigating and cleaning-up the area. Groundwater monitoring at the site is ongoing, and we have installed and continue to install vapor mitigation systems at residences within the groundwater plume. In addition, we are further assessing groundwater conditions. In September 2015, the EPA issued a modification to the site’s RCRA permit that requires us to dredge mercury contamination from a 36-acre area of the lake and remove sediment from two other areas of the lake near the shoreline. The remediation activities commenced when permits and implementation plans were approved in May 2016, and work on the lake dredging project is now complete.

#### U.S. Smelter and Lead Refinery, Inc., East Chicago, Indiana

The U.S. Smelter and Lead Refinery, Inc. (“USS Lead”) Superfund site is located in the Calumet neighborhood of East Chicago, Lake County, Indiana. The site includes the former USS Lead facility along with nearby commercial, municipal, and residential areas. The primary compounds of interest are lead and arsenic, which may be found in soils within the impacted area. The EPA is directing and organizing remediation on this site, and we are one of a number of parties working cooperatively with the EPA on the safe and timely completion of this work. DuPont’s former East Chicago manufacturing facility was located adjacent to the site, and DuPont assigned responsibility for the site to us in the separation agreement.

The USS Lead Superfund site was listed on the National Priorities List in 2009. To facilitate negotiations with PRPs, the EPA divided the residential part of the USS Lead Superfund site into three zones, referred to as Zone 1, Zone 2, and Zone 3. The division into three zones resulted in Atlantic Richfield Co. (“Atlantic Richfield”) and DuPont entering into an agreement in 2014 with the EPA and the State of Indiana to reimburse the EPA’s costs to implement clean-up in Zone 1 and Zone 3. More recently, in March 2017, we and three other parties – Atlantic Richfield, DuPont, and the U.S. Metals Refining Co. (“U.S. Metals”) – entered into an administrative order on consent to reimburse the EPA’s costs to clean-up a portion of Zone 2. In March 2018, the EPA issued a Unilateral Administrative Order for the remainder of the Zone 2 work to five parties, including us, Atlantic Richfield, DuPont, U.S. Metals, and USS Lead Muller Group, and these parties have entered into an interim allocation agreement to complete that work by the end of 2019. There is uncertainty as to whether these parties will be able to agree on a final allocation for Zone 2 and/or the other Zones, and whether any additional PRPs may be identified.

The environmental accrual for USS Lead continues to be based on the 2012 Record of Decision (“ROD”) and Statement of Work for Zone 1 and the associated portion of Zone 3 not yet completed, as well as the current estimate of our share of remaining Zone 2 clean-up. The EPA released a proposed amendment to the 2012 ROD for a portion of Zone 1 in December 2018 (following its August 2018 Feasibility Study Addendum), with its recommended option based on future residential use. However, the proposed amendment was sent out for public comment with the EPA’s statement that the remedy basis and cost may change based on community input on future land use. The EPA’s final decision was expected sometime in the first half of 2019, but has not yet been released. We expect that our future costs for Zone 1 will be contingent on this remedy decision, as well as any final allocation between PRPs.

### New Jersey Department of Environmental Protection Directives and Litigation

In March 2019, the NJ DEP issued two Directives and filed four lawsuits against Chemours and other defendants. Further discussion related to these matters is included in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements.*

### PFOA

See our discussion under the heading “PFOA” in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements.*

### GenX

On June 26, 2019 the Member States Committee of the European Chemicals Agency (“ECHA”) voted to list HFPO Dimer Acid as a Substance of Very High Concern. The vote was based on Article 57(f) – equivalent level of concern having probable serious effects to the environment. This identification does not impose immediate regulatory restriction or obligations, but may lead to a future authorization or restriction of the substance. On September 24, 2019 Chemours filed an application with the EU Court of Justice for the annulment of the decision of ECHA to list HFPO Dimer Acid as a Substance of Very High Concern.

### Delaware Chancery Court Lawsuit

In May 2019, we filed a lawsuit in Delaware Chancery Court (“Chancery Court”) against DowDuPont, Inc., Corteva, Inc., and DuPont concerning DuPont’s contention that it is entitled to unlimited indemnity from us for specified liabilities that DuPont assigned to us in the spin-off. The lawsuit requests that the Chancery Court enter a declaratory judgment limiting DuPont’s indemnification rights against us and the transfer of liabilities to us to the actual “high-end maximum realistic exposures” it stated in connection with the spin-off, or, in the alternative, requiring the return of the approximate $4 billion dividend DuPont extracted from us in connection with the spin-off. In response, DuPont has filed a Motion to Dismiss the lawsuit seeking to have the dispute heard in a non-public arbitration rather than the Chancery Court. Many of the potential litigation liabilities discussed in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements* are at issue in the lawsuit.

### Non-GAAP Financial Measures

We prepare our interim consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”). To supplement our financial information presented in accordance with GAAP, we provide the following non-GAAP financial measures – Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Share (“EPS”), Free Cash Flows (“FCF”), and Return on Invested Capital (“ROIC”) – in order to clarify and provide investors with a better understanding of our performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision-making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our CODM.

Adjusted EBITDA is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of business or assets; and,
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

Adjusted Net Income is defined as our net income or loss, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Adjusted EPS is presented on a diluted basis and is calculated by dividing Adjusted Net Income by the weighted-average number of our common shares outstanding, accounting for the dilutive impact of our stock-based compensation awards. FCF is defined as our cash flows provided by (used for) operating activities, less purchases of property, plant, and equipment as shown in our consolidated statements of cash flows. ROIC is defined as Adjusted Earnings before Interest and Taxes (“EBIT”), divided by the average of our invested capital, which amounts to our net debt, plus equity.

We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing our operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, FCF, and ROIC should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this Quarterly Report on Form 10-Q, should be read in conjunction with the *Interim Consolidated Financial Statements* and notes thereto included in this report, as well as the *Consolidated Financial Statements* and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.

The following table sets forth a reconciliation of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS to our net income attributable to Chemours for the three and nine months ended September 30, 2019 and 2018.

*(Dollars in millions, except per share amounts)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| **Net income attributable to Chemours** | $76 | $275 | $265 | $853 |
| Non-operating pension and other post-retirement employee benefit cost (income) | 1 | (4) | (5) | (18) |
| Exchange (gains) losses, net | (5) | 6 | (2) | 4 |
| Restructuring, asset-related, and other charges (1) | 34 | 12 | 49 | 32 |
| Loss on extinguishment of debt | — | — | — | 38 |
| Gain on sales of assets and businesses (2) | (9) | — | (11) | (45) |
| Transaction costs | — | — | 1 | 9 |
| Legal charges (3) | 5 | 34 | 43 | 45 |
| Adjustments made to income taxes (4) | 3 | (41) | 5 | (54) |
| Benefit from income taxes relating to reconciling items (5) | (7) | (11) | (18) | (15) |
| **Adjusted Net Income** | 98 | 271 | 327 | 849 |
| Net income attributable to non-controlling interests | — | — | — | 1 |
| Interest expense, net | 53 | 47 | 156 | 148 |
| Depreciation and amortization | 78 | 71 | 232 | 213 |
| All remaining provision for income taxes | 19 | 46 | 78 | 188 |
| **Adjusted EBITDA** | $248 | $435 | $793 | $1,399 |
| Weighted-average number of common shares outstanding - basic | 163,815,483 | 176,489,881 | 165,254,084 | 178,765,676 |
| Dilutive effect of our employee compensation plans | 1,325,380 | 5,387,244 | 2,780,874 | 5,891,072 |
| Weighted-average number of common shares outstanding - diluted | 165,140,863 | 181,877,125 | 168,034,958 | 184,656,748 |
| **Per share data** |  |  |  |  |
| Basic earnings per share of common stock | $0.46 | $1.56 | $1.60 | $4.77 |
| Diluted earnings per share of common stock | 0.46 | 1.51 | 1.58 | 4.62 |
| Adjusted basic earnings per share of common stock | 0.60 | 1.54 | 1.97 | 4.75 |
| Adjusted diluted earnings per share of common stock | 0.59 | 1.49 | 1.94 | 4.60 |

(1) Includes restructuring, asset-related, and other charges, which are discussed in further detail in “Note 5 – Restructuring, Asset-related, and Other Charges” to the Interim Consolidated Financial Statements.

(2) For the three and nine months ended September 30, 2019, the Company recognized a non-cash gain of $9 million related to the sale of the Company’s Repauno, New Jersey site. For the nine months ended September 30, 2018, gain on sales of assets and businesses included a $42 million gain associated with the sale of our Linden, New Jersey site.

(3) Includes litigation settlements, PFOA drinking water treatment accruals, and other legal charges. For the three and nine months ended September 30, 2019, legal charges included $2 million and $36 million in additional charges for the approved final Consent Order associated with certain matters at our Fayetteville, North Carolina facility, which are discussed in further detail in “Note 19 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

(4) Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as the benefit from windfalls on our share-based payments, historical valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.

(5) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and represents both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

The following table sets forth a reconciliation of FCF to our cash flows provided by operating activities for the nine months ended September 30, 2019 and 2018.

*(Dollars in millions)*

|  | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Cash flows provided by operating activities | $250 | $881 |
| Less: Purchases of property, plant, and equipment | (385) | (344) |
| **Free Cash Flows** | $(135) | $537 |

The following table sets forth a reconciliation of invested capital, net, a component of ROIC, to our total debt, equity, and cash and cash equivalents at September 30, 2019 and 2018.

*(Dollars in millions)*

|  | Period Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Adjusted EBITDA (1) | $1,134 | $1,794 |
| Less: Depreciation and amortization (1) | (303) | (281) |
| **Adjusted EBIT** | 831 | 1,513 |
| Total debt | 4,156 | 3,999 |
| Total equity | 843 | 1,146 |
| Less: Cash and cash equivalents | (694) | (1,275) |
| **Invested capital, net** | $4,305 | $3,870 |
| Average invested capital (2) | $4,094 | $3,637 |
| **Return on Invested Capital** | 20.3% | 41.6% |

(1) Based on amounts for the trailing 12 months ended September 30, 2019 and 2018. Reconciliations of Adjusted EBITDA to net income attributable to Chemours are provided on a quarterly basis. See the preceding table for the reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three and nine months ended September 30, 2019 and 2018.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.

## Market risk

As filed, 5,233 characters.

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities, and cash flows denominated in a variety of foreign currencies. We are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on our future cash flows and earnings. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

By using derivative financial instruments, we are subject to credit and market risk. The fair values of the derivative financial instruments are determined by using valuation models whose inputs are derived using market observable inputs, and reflects the asset or liability position as of the end of each reporting period. When the fair value of a derivative contract is positive, the counterparty owes us, thus creating a receivable risk for us. We are exposed to counterparty credit risk in the event of non-performance by counterparties to our derivative agreements. We minimize counterparty credit (or repayment) risk by entering into transactions with major financial institutions of investment grade credit ratings.

### Foreign Currency Risks

We enter into foreign currency forward contracts to minimize the volatility in our earnings related to foreign exchange gains and losses resulting from remeasuring our monetary assets and liabilities that are denominated in non-functional currencies, and any gains and losses from the foreign currency forward contracts are intended to be offset by any gains or losses from the remeasurement of the underlying monetary assets and liabilities. These derivatives are stand-alone and, except as described below, have not been designated as a hedge. At September 30, 2019, we had 13 foreign currency forward contracts outstanding, with an aggregate gross notional U.S. dollar equivalent of $399 million, the fair value of which amounted to a net gain of less than $1 million. At December 31, 2018, we had 20 foreign currency forward contracts outstanding, with an aggregate gross notional U.S. dollar equivalent of $503 million, the fair value of which amounted to less than $1 million. We recognized net gains of $1 million and less than $1 million for the three and nine months ended September 30, 2019, respectively, and net gains of $14 million and $8 million for the three and nine months ended September 30, 2018, respectively, within other income, net related to our non-designated foreign currency forward contracts.

We enter certain qualifying foreign currency forward contracts under a cash flow hedge program to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of our international subsidiaries that use the euro as their functional currency. At September 30, 2019, we had 142 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of $128 million, the fair value of which amounted to $4 million of net unrealized gain. At December 31, 2018, we had 75 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of $143 million, the fair value of which amounted to $3 million of net unrealized gain. We recognized pre-tax gains of $5 million and $7 million for the three and nine months ended September 30, 2019, and a pre-tax loss of $1 million and a pre-tax gain of $6 million for the three and nine months ended September 30, 2018, on our cash flow hedge within accumulated other comprehensive loss. For the three and nine months ended September 30, 2019, $2 million and $8 million of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively. For the three and nine months ended September 30, 2018 $1 million of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss.

We designated our euro-denominated debt as a hedge of our net investment in certain of our international subsidiaries that use the euro as their functional currency in order to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar. We recognized pre-tax gains of $33 million and $36 million for the three and nine months ended September 30, 2019, respectively, and a pre-tax loss of $11 million and a pre-tax gain of $2 million for the three and nine months ended September 30, 2018, respectively, on our net investment hedge within accumulated other comprehensive loss.

Our risk management programs and the underlying exposures are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the changes in the value of the underlying exposures. See “Note 22 – Financial Instruments” to the *Interim Consolidated Financial Statements* for further information.

## Controls and procedures

As filed, 1,410 characters.

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (“Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange Commission (“SEC”). These controls and procedures also provide reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), to allow timely decisions regarding required disclosures.

As of September 30, 2019, our CEO and CFO, together with management, conducted an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

### Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 137 characters.

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

Filed Nov 5, 2019.
Source: SEC EDGAR, the filing index for accession 0001564590-19-040478. Last ingested by Listed: Nov 5, 2026, 19:57 ET. No prices; not investment advice.
